Study of Cell Transplantation in Medicare Multiple Myeloma Subjects

IRB/UVA Tracking #
Principal Investigator
Leonid Volodin
Gianna Strand
Contact Email
Contact Phone
Official Trial Title
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries with Multiple Myeloma: A Study to Develop Evidence of Effectiveness for the Centers for Medicare and Medicaid Services (CMS)
Study Description

The University of Virginia Cancer Center seeks adults ages 18 or older for a research study that collects information about Multiple Myeloma and cell transplantation. This study will compare outcomes between patients who receive allogeneic hematopoietic cell transplantation (alloHCT) for their disease and patient who receive standard treatment. You may be able to participate in this study if you are:
- a Medicare beneficiary,
- have Stage II or III multiple myeloma, and
- will receive an allogeneic stem cell transplant in the US.

By participating in this study, Medicare may pay for your stem cell transplant. The study will collect data on participants health for up to 5 years.